Hormones, herbal preparations and nutriceuticals for a better life after the menopause: Part II

Climacteric

Volumn 18, Issue 3, 2015, Pages 364-371

  Comhaire, F H ^a   Depypere, H T ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Herbal preparations; Hormones; Menopause; Nutriceuticals

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; DIOSCOREA VILLOSA EXTRACT; HERBACEOUS AGENT; HOPFLAVONOID DERIVATIVE; HORMONE; ISOFLAVONE DERIVATIVE; LEPIDIUM MEYENII EXTRACT; LINSEED OIL; NUTRACEUTICAL; PINE BARK EXTRACT; UNCLASSIFIED DRUG; VITEX AGNUS CASTUS EXTRACT; ESTRADIOL; PLANT EXTRACT;

ACTAEA RACEMOSA; ARTICLE; BREAST CANCER; BROCCOLI; BRUSSELS SPROUT; CABBAGE; CANCER PREVENTION; COLON CANCER; DIET SUPPLEMENTATION; DIOSCOREA VILLOSA; DNA METHYLATION; ESTROGEN METABOLISM; ESTROGEN THERAPY; FEMALE; HUMAN; LEPIDIUM; LEPIDIUM MEYENII; LINSEED; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHYTOTHERAPY; PINE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAVOY CABBAGE; SOYBEAN; VASOMOTOR DISORDER; VITEX AGNUS CASTUS; YAM; POSTMENOPAUSE;

DIETARY SUPPLEMENTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; QUALITY OF LIFE;

EID: 84929324161     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.985646     Document Type: Article

References (107)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Pricipal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. Burger HG, Maclennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:381-7
3. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241-9
4. Sood R, Faubion SS, Kuhle CL, Thiele JM, Shuster L T. Prescribing menopausal hormone therapy: an evidence-base approach. Int J Womens Health 2014;6:47-57
5. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended followup of Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476-86
6. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
7. Depypere H, Comhaire F. Herbal preparations for the menopause: Beyond isoflavones and black cohosh. Maturitas 2014;77:191-4
8. Comhaire FH, Depypere HT. Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I. Climacteric 2015;18:358-63
9. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012;19:776-90
10. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013 dec 10;12:CD 001395. pub4
11. Nikander E, Kikkinen A, Metsä-Heikkilä M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in the treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213-20
12. Cancelo Hidalgo MJ, Castelo Branco C. Optimizing soy isoflavones effect in postmenopausal women: the impact of timing on climacteric symptoms. Gynecol Endocrinol 2011;27:696-700
13. Gold EB, Leung K, Crawford SL, et al. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause 2013;20:305-14
14. Bolca S, Possemiers S, Herregat A, et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 2007;137:2242-6
15. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-9
16. Aso T, Uchiyama S, Matsumura Y, et al. A natural S-(-) equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal japanese women. J Womens Health (Larchmt) 2012;21:92-100
17. Decroos K, Eeckhaut E, Possemiers S, Verstraete W. Administration of equol-producing bacteria alters the equol production status in the Simulator of the Gastrointestinal Microbial Ecosystem (SHIME). J Nutr 2006;136:946-52
18. Qin W, Zhu W, Shi H, et al. Soy isoflavones have antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr Cancer 2009;61:238-44
19. Wada K, Nakamura K, Tamai Y, et al. Soy isoflavone intake and breast cancer risk in Japan: from the Takayama study. Int J Cancer 2013;133:952-60
20. Steinberg FM, Murray MJ, Lewis RD, et al. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J Clin Nutr 2011;93:356-67
21. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr 2012;96:123-32
22. Cassidy A, Albertazzi P, Lise-Nielsen I, et al. Critical review of health effects of soybean phyto-oestrogens in post-menopausal women. Proc Nutr Soc 2006;65:76-92
23. Delmanto A, Nahas-Neto J, Traiman P, et al. Effects of soy isoflavones on mammographic density and breast parenchyma in postmenopausal women: a randomized, double blind, placebo-controlled clinical trial. Menopause 2013;20:1049-54
24. Khan SA, Chatterton RT, Michel N, et al. Soy isoflavone supplementation for breast cancer risk reduction: a randomised phase II trial. Cancer Prev Res (Phila) 2012;5:309-19
25. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008;16:219-26
26. Guha N, Kwan ML, Quesenberry CP, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009;118:395-405
27. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104:326-39
28. Falk RT, Brinton LA, Dorgan JF, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res 2013;15:R34
29. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16 alpha/2-hydoxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 1995;103(Suppl 7):147-50
30. Bernal AJ, Jirtle RL. Epigenomic disruption: the effects of early development exposures. Birth Defects Res A Clin Mol Teratol 2010;88:938-44
31. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 2007;146:839-47
32. Soni M, Rahardjo TB, Soekardi R, et al. Phytoestrogens and cognitive function: a review. Maturitas 2014;77:209-20
33. Zang Y, Li Q, Chen H. DNA methylation and histone modifications of Wny genes by genistein during colon cancer development. Carcinogenesis 2013;34:1756-63
34. Noreen F, Röösli M, Gaj P, et al. Modulation of age- and cancerassociated DNA methylation change in the healthy colon by aspirin and lifestyle. J Natl Cancer Inst 2014;106. Pii:dju161
35. Qi W, Weber CR, Wasland K, Savkovic SD. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOX03 activity. BMC Cancer 2011;11:219
36. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev 2012 Sept 12;9:CD007244
37. Guzman G, Kallwitz ER, Wojewoda C, et al. Liver injury with features mimicking autoimmune hepatitis following the use of Black Cohosh. Case Report Med 2009:918156
38. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, et al. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011;10:249-59
39. Medicines and Healthcare products Regulatory Agency (MHRA). Liver failure case highlights need to use Black Cohosh remedies carefully. MHRA press release; 29 october, 2012. press.office@mhra.psi.gov. uk
40. Bebenek M, Kemmler W, van Stengel S, et al. Effect of exercise and Cimicifuga racemosa (CR BNO 1055) on bone mineral density, 10-year coronary heart disease risk, and menopausal complaints: the randomized controlled Training and Cimicifuga racemosa Erlangen (TRACE) study. Menopause 2010;17:791-800
41. Laakmann E, Grajecki D, Doege K, zu Eulenburg C, Buhling KJ. Efficacy of Cimicifuga racemosa, Hypericum perforatum and Agnus castus in the treatment of climacteric complaints: a systematic review. Gynecol Endocrinol 2012;28:703-9
42. Overk CR, Yao P, Chadwick LR, et al. Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense). J Agric Chem 2005;53:6246-53
43. Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. A first prospective, randomized, double-blind, placebocontrolled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 2006;54:164-75
44. Erkkola R, Vervarcke S, Vansteelandt S, et al. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine 2010;17:389-96
45. Hemachandra LP, Madhubhani P, Chandrasena R, et al. Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A). Cancer Prev Res (Phila) 2012;5:73-81
46. Bolca S, Li J, Nikoloic D, et al. Disposition of hop pregnyl flavonoids in human breast tissue. Mol Nutr Food Res 2010;54(Suppl 2):S284-94
47. Bulzomi P, Bolli A, Galluzzo P, et al. The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against high bisphenol a background. IUBMB Life 2012;64:690-6
48. Dhooge W, Eertmans F, Comhaire F. Estrogen receptor based in vitro essays for the evaluation of endocrine disrupters. Folia Histochem Cytobiol 2001;39(Suppl 2):44-5
49. Lee MS, Shin BC, Yang EJ, Lim HJ, Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas 2011;70:227-33
50. Chiang SS, Chang SP, Pan TM. Osteoprotective effect of monascus-fermented Dioscorea in ovariectomized rat model of postmenopausal osteoporosis. J Agric Food Chem 2011;59:9150-7
51. Colli MC, Bracht A, Soares AA, et al. Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms. J Med Food 2012;15:840-5
52. Pruthi S, Qin R, Terstreip SA, et al. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 2011;19:48-53
53. Brooks JD, Ward WE, Lewis JE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr 2004;79:318-25
54. Wang C, Mäkelä T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994;50:205-12
55. Sonestedt E, Ivarsson MI, Harlid S, et al. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009;139:993-1001
56. Zamora-Ros R, Ferrari P, Gonzáles CA, et al. Dietary flavonoid and lignan intake and breast cancer risk according to menopause and hormone receptor status in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Breast Cancer Res Treat 2013;139:163-76
57. Buck K, Zaineddin AK, Vrieling A, et al. Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 2011;105:1151-7
58. Peterson J, Dwyer J, Adlercreutz H, Scalbert A, Jacques P, McCullough ML. Dietary lignans: physiology and potential for cardiovascular disease risk reduction. Nutr Rev 2010;68:571-603
59. Schäfer A, Chovanova Z, Muchova J, et al. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60:5-9
60. Grimm T, Chovanova Z, Michova J, et al. Inhibition of NF-kB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflamm 2006;3:1
61. Kohama T, Negami M. Effect of low-dose french maritime pine bark extract on climacteric syndrome in 170 perimenopausal women. J Reprod Med 2013;58:39-46
62. Devaraj S, Vega-Lopez S, Kaul N, et al. Supplementation with pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters plasma lipoprotein profile. Lipids 2002;37:931-4
63. Tresserra-Rimbau A, Rimm EB, Medina-Remon A, et al. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. Nutr Metab Cardiovasc Dis 2014;24:639-47
64. Treserra-Rimbau A, Rimm EB, Medina-Remón A, et al. Polyphemol intake and mortality risk: a re-analysis of the PREDIMED trial. BMC Med 2014;12:77
65. Acharya A, Das I, Singh S, Saha T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat Food Nutrit Agric 2010;2:166-7
66. Morrison J, Multell D, Pollock TA, et al. Effects of dried cruciferous powder on raising 2/16 hydroxyestrogen ratios in premenopausal women. Altern Ther Health Med 2009;15:52-3
67. Thomson CA, Rock CL, Caan BJ, et al. Increase in cruciferous vegetable intake in women previously treated for breast cancer participating in a dietary intervention trial. Nutr Cancer 2007;57:11-19
68. Liu X, Lv K. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. Breast 2013;22:309-13
69. Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009;89:1799-807
70. Panossian A, Wikman G, Kaur P, Asea A. Adaptogens stimulate neuropeptide y and hsp72 expression and release in neuroglia cells. Front Neurosci 2012;6:6
71. Scott G. Antioxidants in Science, Technology, Medicine and Nutrition. Chichester, UK: Albion Publishing Ltd, 1997
72. Kalra EK. Nutraceutical - definition and introduction. AAPS PharmSci 2003;5(3):article 25 (http://www.pharmsci.org)
73. Wang L, Sesso HD, Glynn RJ, et al. Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in Physicians' Health Study II randomized trial. Am J Clin Nutr 2014;100:915-23
74. World Health Organization. WHO traditional medicine strategy 2014-2023. http://www.who.int/iris/handle/10665/92455
75. Goldman DP, Cutler D, Rowe JW, et al. Substantial health and economic returns from delayed aging may warrant new focus for medical research. Health Aff (Millwood) 2013;32:1698-705
76. Michaëlsson K, Wolk A, Byberg L, Arnlöv J, Melhus H. Intake and serum concentrations of α-tocopherol in relation to fractures in elderly women and men: 2 cohort studies. Am J Clin Nutr 2014;99:107-14
77. Mainini G, Rotondi M, Di Nola K, et al. Oral supplement with antioxidant agents containing alpha lipoic acid: effects on postmenopausal bone mass. Clin Exp Obstet Gynecol 2012;39:489-93
78. Hager K, Kenklies M, McAfoose J, Engel J, Münch G. Alphalipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. J Neural Transm 2007; Suppl 72:189-193.
79. Lee BJ, Huang YC, Chen SJ, Lin PT. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012;28:250-5
80. Hoeg A, Gogakos A, Murphy E, et al. Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 2012;97:4061-70
81. Pan SY, Zhou J, Gibbons L, et al. Antioxidants and breast cancer risk - a population-based case-control study in Canada. BMC Cancer 2011;11:372
82. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006;63:1545-50
83. Vakhapova V, Cohen T, Richter Y, Herzog Y, Corczyn AD. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord 2010;29:467-74
84. Gariballa SE, Forster SJ, Powers HJ. Effects of mixed dietary supplements on total plasma homocysteine concentration (tHcy): a randomized, double-blind, placebo-controlled trial. Int J Vitam Nutr Res 2012;82:260-6
85. De Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocystein-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry 2012;27:592-600
86. Nachum-Biala Y, Troen AM. B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors 2012;38:145-50
87. Saposnik G, Ray JG, Sheridan P, et al. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009;40:1365-72
88. Marti-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2013 Jan 31;1:CD006612
89. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA 2013;110:9523-8
90. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009;32:365-72
91. Kotwal S, Jun. M, Sullivan D, Perkavic V, Neal B. Omega 3 fatty acids and cardiovascular outcomes: systematic review and metaanalysis. Circ Cardiovasc Qual Outcomes 2012;5:808-18
92. Hansen-Krone IJ, Enga KF, Südduth-Klinger JM, et al. High fish plus oil intake is associated with slightly reduced risk of venous thromboembolism: The TromsöStudy. J Nutr 2014;144:861-7
93. Tierney AC, McMonagle J, Shaw DI, et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome - LIPGENE: a European randomized dietary intervention study. Int J Obes 2011;35:800-9
94. Kiecold-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 2012;26:988-95
95. Mozaffarian D, Lemaitre RN, King IB, et al. Plasma phospholipid long-chain ? 3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med 2013;158:515-25
96. Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem 2013;329:73-132
97. Park LK, Friso S, Choi SW. Nutritional influences on epigenics and age related disease. Proc Nutr Soc 2012;71:75-83
98. Gaziano JM, Howard D, Sesso HD, et al. Multivitamins in the prevention of cancer in men: The Physicians' Health Study III randomized controlled trial. JAMA 2012;308:1751-60
99. Chaumontet C, Bex V, Véran F, Martel P. The vitamin E analog tocopherol succinate strongly inhibits gap junctional intercellular communication in rat liver epithelial cells (IAR203). J Nutr Biochem 2008;19:263-8
100. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009;301:52-62
101. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Cartotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-9
102. Neuhouser ML, Barnett MJ, Kristal AR, et al. Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2009;18:2202-6
103. Bernard D, Christophe A, Delanghe J, et al. The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep 2003;8:41-6
104. Mursu J, Robien K, Harnack LJ, et al. Dietary supplements and mortality in older women: the Iowa Women's Health Study. Arch Intern Med 2011;171:1625-33
105. Fabian E, Bogner M, Kickinger A, et al. Intake of medication and vitamin status in the elderly. Ann Nutr Metab 2011;58:118-25
106. Ulbricht C. The top five nutritional deficiencies in the United States. Alternat Compl Ther 2013;19:119-22
107. Ames BN. Low micronutrient intake amy accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci USA 2006;103:17589-94